Treatments for chronic myeloid leukemia (CML) represent a success story in molecular
medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the …

The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …

The treatment of chronic myelogenous leukemia (CML) has been revolutionized by the
development of the small-molecule tyrosine kinase inhibitor imatinib. The primary target for …

Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia
chromosome and oncogenic signaling by the resulting Bcr–Abl fusion protein …

Identification of BCR‐ABL as the defining leukemogenic event in chronic myelogenous
leukemia (CML) revolutionized the treatment of the disease. Imatinib, a potent BCR‐ABL …

Purpose: Review the state-of-art knowledge of the biology and therapy of chronic
myelogenous leukemia (CML). Experimental Design: A review of the literature was …

Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …

The treatment of chronic myeloid leukemia (CML) drastically changed with the introduction
of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), in 1998. By directly targeting …

The introduction of the tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, and nilotinib has
dramatically improved the treatment of chronic myeloid leukemia (CML). However, a minority …

A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will
require alternative therapy at some point owing to safety reasons or lack of efficacy …